CN-117187371-B - Marker for predicting cerebral apoplexy recurrence and application thereof

Abstract

The application provides a marker for predicting cerebral apoplexy recurrence and application thereof. The marker is obtained by screening based on a large number of cerebral apoplexy samples. The methylation marker disclosed by the application can accurately predict the recurrence risk of a stroke patient, can give accurate prompt to the recurrence time point of the patient possibility through systematic analysis of the past basic information, the flow regulation information and the detection result of an individual, further provides guidance for accurate treatment and health management, and has important clinical application value.

Inventors

• TIAN JICHAO
• YANG YADONG
• YE JIANWEI
• WANG XIAOQI
• PENG YONGFEI
• HU QIUWEN
• YE ZHIHAI
• HAN XIAOLIANG
• WANG JIANMING

Assignees

• 博尔诚（北京）科技有限公司

Dates

Publication Date

20260512

Application Date

20230410

Priority Date

20220408

Claims (8)

1. 1. The application of the methylation marker in preparing a kit for predicting cerebral apoplexy recurrence, wherein the target sequence of the methylation marker is a sequence shown as SEQ ID NO. 1.
2. 2. The use according to claim 1, wherein the stroke is selected from one or more of a large atherosclerotic stroke, a cardiac cerebral embolism, an arteriolar occlusive stroke, an ischemic stroke and a cerebral infarction.
3. 3. The use of claim 1, wherein the stroke recurrence is a stroke recurrence within three months.
4. 4. A composition for predicting recurrence of stroke, the composition comprising: Nucleic acids for detecting the methylation state of a methylation marker, Wherein the methylation state of the methylation marker is characterized by methylation of a target sequence of the methylation marker, The target sequence of the methylation marker is a sequence shown as SEQ ID NO. 1.
5. 5. The composition according to claim 4, wherein the cerebral stroke is one or more selected from the group consisting of a large atherosclerosis stroke, a cardiac cerebral embolism, a arteriole occlusive cerebral stroke, an ischemic cerebral stroke and a cerebral infarction.
6. 6. The composition of claim 4, wherein the stroke recurrence is a stroke recurrence within three months.
7. 7. A kit comprising reagents for detecting a methylation marker, wherein the target sequence of the methylation marker is the sequence shown in SEQ ID No. 1.
8. 8. The kit of claim 7, wherein the sample for detection by the kit comprises a cell line, a histological section, a tissue biopsy, stool, colonic outflow, urine, plasma, serum, whole blood, isolated blood cells, or a combination thereof.

Description

Marker for predicting cerebral apoplexy recurrence and application thereof Technical Field The application belongs to the field of molecular biology, relates to gene detection, and in particular relates to a marker for predicting cerebral apoplexy recurrence and application thereof. Background DNA methylation is one of the major mechanisms of epigenetic modification, playing an important role in maintaining normal cellular function, genetic imprinting, embryo development, and human tumorigenesis, and as technology progresses, methods directed to methylation studies cover almost individual genes to genome levels at various levels. In mammalian cells, DNA methylation is characterized by the addition of a methyl group (-CH 3) to the 5 th carbon atom of the cytosine ring (5-methylcytosine; 5 mC) under the action of DNA methyltransferase (DNMT), and covalent addition of methyl groups usually occurs in cytosine in CpG dinucleotides, which are concentrated in a moiety called CpG island, with clusters of CpG sites occurring at a desired frequency. Aberrant methylation has been associated with most diseases including cancer, neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and the like. Analysis of DNA methylation patterns is critical to understanding the underlying molecular mechanisms of these diseases. In addition, DNA methylation patterns can be used as a basis for clinical management, such as diagnosis, prognosis, and therapeutic response. Cerebral apoplexy is an important cause of death and disability, and the number of people suffering from cerebral apoplexy increases year by year, and the onset age is gradually younger. Clinical data show that the ratio of Progressive Stroke (PS) in acute ischemic stroke patients can reach 26.4% -34%, and no effective diagnosis and treatment means is available, so that higher disability rate and mortality rate can be caused, and a heavy burden is brought to families and clinical work. For a patient suffering from apoplexy, if the patient can be predicted to relapse in time, the death or disability of the patient suffering from apoplexy can be effectively reduced. At present, clinical diagnosis of stroke recurrence is mainly evaluated by clinical data, and no clear molecular marker exists. Disclosure of Invention Based on the problems existing in the existing cerebral apoplexy recurrence detection, the application aims to provide a marker, a composition, a kit and application thereof for predicting cerebral apoplexy recurrence. The specific technical scheme of the application is as follows: 1. A methylation marker for predicting stroke recurrence comprising a genomic region from position 60727176 to 60733176 of chromosome 13 on human reference genome hg 38. 2. The methylation marker according to item 1, wherein the target sequence of the methylation marker is shown as SEQ ID NO. 1, SEQ ID NO.2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 6. 3. The methylation marker according to item 1 or 2, wherein the cerebral stroke is selected from one or two or more of a large atherosclerosis stroke, a cardiac cerebral embolism, an arteriole occlusive cerebral stroke, an ischemic cerebral stroke and a cerebral infarction. 4. The methylation marker of any one of claims 1-3, wherein the stroke recurrence is a stroke recurrence within three months. 5. Use of a methylation marker of any one of items 1-4 in the preparation of a kit for predicting recurrence of stroke. 6. Use of a methylation marker according to any one of claims 1-4 in the manufacture of a medicament for preventing recurrence of stroke, preferably wherein the medicament is a targeted medicament designed based on the methylation marker. 7. A composition for predicting recurrence of stroke, the composition comprising: a nucleic acid for detecting the methylation state of the methylation marker of any one of items 1 to 4, Wherein the methylation state of the methylation marker is characterized by methylation of a target sequence of the methylation marker. 8. A kit comprising reagents for detecting the methylation marker of any one of claims 1-4. 9. The kit of claim 8, wherein the sample for detection comprises a cell line, a histological section, a tissue biopsy/paraffin-embedded tissue, a body fluid, stool, colon effluent, urine, plasma, serum, whole blood, isolated blood cells, cells isolated from blood, or a combination thereof. 10. A nucleic acid for targeting the methylation marker of any one of claims 1-4. The application has the following beneficial effects: The methylation marker disclosed by the application can accurately predict the recurrence risk of a stroke patient, can give accurate prompt to the recurrence time point of the patient possibility through systematic analysis of the past basic information, the flow regulation information and the detection result of an individual, further provides guidance for accurate treatment and health management, and has important clinical appli